StageZero Life Sciences Ltd.
SZLS.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 09/30/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 2.99M | 2.99M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 2.99M | 2.99M |
| Cost of Revenue | -- | -- | -- | 2.56M | 2.67M |
| Gross Profit | -- | -- | -- | 437.50K | 328.20K |
| SG&A Expenses | -- | -- | -- | 4.89M | 4.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | 7.54M | 7.54M |
| Operating Income | -- | -- | -- | -4.55M | -4.55M |
| Income Before Tax | -- | -- | -- | -12.53M | -12.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -- | -12.53 | -12.53 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -12.53M | -12.53M |
| EBIT | -- | -- | -- | -4.55M | -4.55M |
| EBITDA | -- | -- | -- | -4.33M | -4.33M |
| EPS Basic | -- | -- | -- | -0.12 | -0.12 |
| Normalized Basic EPS | -- | -- | -- | -0.03 | -0.03 |
| EPS Diluted | -- | -- | -- | -0.12 | -0.12 |
| Normalized Diluted EPS | -- | -- | -- | -0.03 | -0.03 |
| Average Basic Shares Outstanding | -- | -- | -- | 422.44M | 410.13M |
| Average Diluted Shares Outstanding | -- | -- | -- | 422.44M | 410.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
